Genetics Institute, Inc.

Wyeth

Other

The Johns Hopkins University

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Lori J Fitz

Debra D Donaldson

Clive R Wood

Mary Collins

Matthew James Whitters

Tamlyn Neben

Laura Lin

Jose William Saldanha

Geertruida Machteld Veldman

Lioudmila Tchistiakova

Samuel Goldman

Kimberly Ann Marquette

Xiang-Yang Tan

Angela Widom

Eric Feyfant

Kevin Delos Parris

Marion T Kasaian

Thomas A Wynn

Tania Shane

Marsha Wills-Karp

Amy Sze Pui Tam

Monica G Chiaramonte

Nancy L Wood

Mark L Stahl

Lidia Mosyak

William Stuart Somers

Stephane Olland

Divya Chaudhary

Zhang Bao Xu

Karl Malakian

Scott Wolfrom

Julie Lee

Rita Greco

This application relates to antibodies, e.g., humanized antibodies, and antigen-binding fragments thereof, that bind to interleukin-13 (IL-13), in particular, human IL-13, and their uses in regulating immune responses mediated by IL-13. The antibodies disclosed herein are useful in diagnosing, preventing, and/or treating a subject, e.g., a human patient, one or more IL-13-associated disorders, e.g., respiratory disorders (e.g., asthma); atopic disorders (e.g., allergic rhinitis); inflammatory and/or autoimmune conditions of the skin (e.g., atopic dermatitis), and gastrointestinal organs (e.g., inflammatory bowel diseases (IBD)), as well as fibrotic and cancerous disorders.

Antibodies against human interleukin-13 and uses therefor

Polynucleotides encoding the IL-13 receptor and fragments thereof are disclosed. IL-13 receptor proteins, methods for their production, inhibitors of binding of IL-13 and its receptor and methods for their identification are also disclosed.

Methods of using antibodies to human IL-13bc for inhibiting IL-13 binding

Antibodies against human interleukin-13 and pharmaceutical compositions thereof

A three-dimensional structure of human protein kinase C theta (PKC&#x3b8;) can be used in methods of designing an agent that interacts with PKC&#x3b8;. The agent can be an inhibitor of PKC&#x3b8; activity.

Structure of protein kinase C theta

The present invention is directed to methods for treating asthma.

Method and compositions for treating asthma

Polynucleotides encoding the IL-13 receptor and fragments thereof are disclosed. IL-13 receptor proteins, methods for their production, inhibitors of binding of IL-13 and its receptor and methods for their identification are also disclosed. Methods of medical treatment using such molecules and antagonists of the IL-13/IL-13R interaction are also provided.

Cytokine receptor chain

Methods are provided for treating or inhibiting the formation of tissue fibrosis using IL-13 antagonists, including without limitation soluble forms of the IL-13 receptor.

Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains

Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding

IL-13 receptor proteins, methods for their production, inhibitors of binding of IL-13 and its receptor and methods for their identification are also disclosed.

IL-13 Receptor chain

IL-13 receptor proteins, methods for their production, inhibitors of binding of IL-13 and its receptor methods of mediating-Ig-responses and methods for their identification are also disclosed.

Methods of inhibiting binding and treating Ig-mediated responses with IL-13 receptor

Methods of identifying inhibitors of binding of IL-13 and its receptor and methods for their identification are also disclosed.

Methods of identifying inhibitors of binding of IL-13 to the IL-13 receptor chain

IL-13 cytokine receptor chain

Growing community of inventors

Somerville, MA, United States of America

Lori J Fitz